APRE vs. SPRO, LVTX, AKTX, COEP, FBLG, DYAI, BLUE, KZR, FGEN, and MRNS
Should you be buying Aprea Therapeutics stock or one of its competitors? The main competitors of Aprea Therapeutics include Spero Therapeutics (SPRO), LAVA Therapeutics (LVTX), Akari Therapeutics (AKTX), Coeptis Therapeutics (COEP), FibroBiologics (FBLG), Dyadic International (DYAI), bluebird bio (BLUE), Kezar Life Sciences (KZR), FibroGen (FGEN), and Marinus Pharmaceuticals (MRNS). These companies are all part of the "pharmaceutical products" industry.
Aprea Therapeutics vs.
Aprea Therapeutics (NASDAQ:APRE) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, community ranking, analyst recommendations and risk.
In the previous week, Aprea Therapeutics had 6 more articles in the media than Spero Therapeutics. MarketBeat recorded 7 mentions for Aprea Therapeutics and 1 mentions for Spero Therapeutics. Spero Therapeutics' average media sentiment score of 0.00 beat Aprea Therapeutics' score of -0.16 indicating that Spero Therapeutics is being referred to more favorably in the news media.
Spero Therapeutics received 153 more outperform votes than Aprea Therapeutics when rated by MarketBeat users. Likewise, 69.67% of users gave Spero Therapeutics an outperform vote while only 57.14% of users gave Aprea Therapeutics an outperform vote.
34.2% of Aprea Therapeutics shares are owned by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are owned by institutional investors. 12.8% of Aprea Therapeutics shares are owned by company insiders. Comparatively, 4.5% of Spero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Aprea Therapeutics presently has a consensus target price of $15.50, suggesting a potential upside of 868.75%. Spero Therapeutics has a consensus target price of $5.00, suggesting a potential upside of 629.08%. Given Aprea Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Aprea Therapeutics is more favorable than Spero Therapeutics.
Aprea Therapeutics has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500. Comparatively, Spero Therapeutics has a beta of 0.23, meaning that its stock price is 77% less volatile than the S&P 500.
Spero Therapeutics has a net margin of 3.30% compared to Aprea Therapeutics' net margin of -1,029.50%. Spero Therapeutics' return on equity of 4.03% beat Aprea Therapeutics' return on equity.
Spero Therapeutics has higher revenue and earnings than Aprea Therapeutics. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Spero Therapeutics beats Aprea Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Aprea Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for APRE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aprea Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:APRE) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy APRE Stock Free APRE Stock Alerts